wholly foreign-owned hospitals will be permitted to be established in China
Time:2024-09-08 20:55:34Source:Click:次
According to information from the website of China's Ministry of Commerce on September 8, 2024, the Ministry of Commerce, the National Health Commission, and the National Medical Products Administration have jointly issued a notice regarding the launch of a pilot program to expand openness in the medical field.
The notice outlines plans to introduce foreign investment to promote high-quality development in China's medical sector and better meet the healthcare needs of the population. The program aims to expand openness in the medical field.
In the biotechnology sector, the notice specifies that foreign-invested enterprises will be allowed to engage in the development and application of human stem cells, gene diagnosis, and gene therapy technologies in pilot areas, including the China (Beijing) Pilot Free Trade Zone, China (Shanghai) Pilot Free Trade Zone, China (Guangdong) Pilot Free Trade Zone, and Hainan Free Trade Port. These activities will be permitted for product registration and production purposes. Once approved and registered, these products may be used nationwide. Foreign-invested enterprises participating in the pilot program must comply with China's laws and regulations, including those related to the management of human genetic resources, clinical drug trials (including international multi-center trials), drug registration and production, and ethical review processes, following the necessary procedures.
In the field of wholly foreign-owned hospitals, the notice clarifies that foreign investors will be permitted to establish hospitals in Beijing, Tianjin, Shanghai, Nanjing, Suzhou, Fuzhou, Guangzhou, Shenzhen, and the entire island of Hainan (excluding traditional Chinese medicine hospitals and public hospital mergers). Specific conditions, requirements, and procedures for setting up such hospitals will be announced separately.
